TITLE

Deals roundup

PUB. DATE
September 2008
SOURCE
Medical Device Daily;9/23/2008, Vol. 12 Issue 203, p3
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on the exclusive rights secured by Sequenom involving fundamental patent rights for digital polymerase chain reaction (PCR) technologies and methods under a licensing agreement with Genomic Nanosystems. The licensed rights include U.S. Patent Numbers 6,143,496 and 6,291,559 and patent pending applications. Such addition will also give Sequenom the right to use digital PCR methods on any platform for prenatal diagnostics and analysis for any sample.
ACCESSION #
34487136

 

Related Articles

  • Deals roundup.  // Medical Device Daily;10/31/2008, Vol. 12 Issue 213, p3 

    The article reports on the exclusive licensing agreement between Xenomics and Sequenom. Under the agreement, the latter will be given exclusive rights to use the patents of the former for the development of prenatal research and diagnostic products. Xenomics also has patents in other fields of...

  • The effects of business practices, licensing, and intellectual property on development and dissemination of the polymerase chain reaction: case study. Fore Jr., Joe; Wiechers, Ilse R.; Cook-Deegan, Robert // Journal of Biomedical Discovery & Collaboration;2006, Vol. 1, p7 

    Introduction: Polymerase chain reaction (PCR) was a seminal genomic technology discovered, developed, and patented in an industry setting. Since the first of its core patents expired in March, 2005, we are in a position to view the entire lifespan of the patent, examining how the intellectual...

  • Agreements/contracts.  // Medical Device Daily;9/17/2008, Vol. 12 Issue 199, p4 

    The article reports on the announcement by Sequenom that it has acquired exclusive worldwide rights to digital polymerase chain reaction (PCR) and other noninvasive prenatal diagnostic intellectual property from The Chinese University in Hong Kong, China. It states that the rights will expand...

  • Rapid trisomy diagnosis (21, 18, and 13) using flourescent PCR and short tandem repeats:... Findlay, Ian; Toth, Tamas; Matthews, Paul; Marton, Tamás; Quirke, Philip; Papp, Zoltán // Journal of Assisted Reproduction & Genetics;May98, Vol. 15 Issue 5, p266 

    Presents a study which was conducted to determine whether flourescent polymerase chain reaction (PCR) could be of use in a prenatal diagnostic setting. How prenatal diagnosis of fetal trisomies is usually performed; What this requires; What the quantitative nature of PCR allows; How the study...

  • TrovaGene Inc. Confirms It Has Regained Its Rights to Transrenal Technology for Non-Invasive Prenatal Testing and Cancer.  // Biomedical Market Newsletter;8/12/2011, Vol. 21, p352 

    The article reports that TrovaGene Inc. has regained its rights to transrenal technology for non-invasive prenatal applications and cancer by terminating its license agreement with Sequenom Inc. Thomas Adams, TrovaGene's chairman, says that the recovery gives them the opportunity to expand their...

  • Fluidigm and Life Technologies Cross-License a Broad Set of Intellectual Properties.  // Biomedical Market Newsletter;7/14/2011, p9 

    The article reports on the cross-licensing and sub-licensing agreements by Fluidigm Corp. for a range of intellectual properties of Life Technologies Inc. It says that under the deal, Fluidigm and Life will gain broad access to each company's patents for imaging readers and other technologies...

  • U.S. patent covers most real-time PCR instruments.  // Medical Device Daily;4/5/2010, Vol. 14 Issue 64, p4 

    The article deals with the granting of the U.S. Patent No. 7,670,832 by the U.S. Patent and Trademark Office (PTO) in April 2010 to include most of the real-time polymerase chain reaction (PCR) instruments on the market.

  • Diatherix acquires patent to Tem-PCR from Qiagen.  // Medical Device Daily;8/8/2013, Vol. 17 Issue 152, p3 

    The article announces that Hunstville, Alabama-based Diatherix Laboratories has acquired from Qiagen of Venlo, the Netherlands, the patent to Tem-PCR, a diagnostic testing technology that allows for rapid identification of multiple infectious disease organisms.

  • Very early prenatal diagnosis on coelomic cells using quantitative fluorescent polymerase chain reaction. Jauniaux, Eric; Cirigliano, Vincenzo; Adinolfi, Matteo // Reproductive BioMedicine Online (Reproductive Healthcare Limited;Jun2003, Vol. 6 Issue 4, p494 

    Presents a study that assessed the possibility of using the quantitative fluorescent polymerase chain reaction assay performed on DNA extracted from cells present in the extra-embryonic coelom for the detection of aneuploidies in prenatal diagnosis. Materials and methods; Results of the study.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics